The present study has investigated the prognostic value of baseline serum beta-2 microglobulin in patients with DLBCL treated with R-CHOP immunochemotherapy and externally validated its prognostic impact in an independent validation cohort. Here, B2M is linked to diffuse large B-cell lymphoma.